This research summary highlights new coverage of SAB Biotherapeutics and an earnings preview for Hawaiian Electric Inds. It provides revised ratings, price targets, and EPS estimates.
Key Takeaways
- 1.SAB Biotherapeutics initiated at Overweight with a USD 13 price target, citing potential in the T1D market.
- 2.Hawaiian Electric Inds remains Equal Weight; earnings focus is on rate rebasing and liquidity.
Table of Contents
- Summary of Changes
- Company Research
- Publications Summary
- Healthcare
- Power & Utilities
- Explanation of Summary of Changes table
- Analyst(s) Certification(s)
- Important Disclosures
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Eliana MerleMichael LoneganNicholas Campanella
Securities
SABSHE
Themes
Biotechnology R&DUtility Rate Regulation
Regions
North AmericaUnited States